Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 279

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Open access
Gupta, Anil, Gonzalez-Rojas, Yaneicy, Juarez, Erick, Crespo Casal, Manuel, Moya, Jaynier, Rodrigues Falci, Diego, Sarkis, Elias, Solis, Joel, Zheng, Hanzhe, Scott, Nicola, Cathcart, Andrea L., Parra, Sergio, Sager, Jennifer E., Austin, Daren, Peppercorn, Amanda, Alexander, Elizabeth, Yeh, Wendy W., Brinson, Cynthia, Aldinger, Melissa, Shapiro, Adrienne E., COMET-ICE Investigators, Free, Almena, Johnson, Kimball, Cordasco, Edward, Little, Raymond, Bajwa, Ali, Doshi, Ankur, Focil, Augusto, Hussain, Rubaba (Rubie), Bostick, Greg, Somodevilla, Guillermo, Ali, Hasan, Kowalczyk, John, Mittal, Shilpi, Caso, Jorge, Goisse, Marcy, Espinal, Ladynez, Zepeda, Luis, Nguyen, Thinh, Martinez, Luis, Alvarez, German, Pucillo, Ronald, Seep, Michael, Parikh, Naval, Escobar, Victor, Curra, Armando, Dal Maso, Vinicius, O'Mahony, John, Ramacciotti, Eduardo, Diaz, Jorge, Luz, Kleber, Ruane, Peter, Mochlera, Bharat, Roldan Sanchez, Juan, Hernandez, Luis, Fernandez, Alfredo, Leavitt, Glenn, Azizad, Masoud, Afzal, Haider, Fatakia, Adil, Narejos Perez, Silvia, Stadnik, Claudio Marcel, Gorgos, Linda, Sachdeva, Yessica, Segura, Patricia, Quandros, Carlos, Perry, Russell, Sher, Lawrence · 2022 · JAMA

Abstract

Importance: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of high-risk patients to prevent COVID-19 progression. Objective: To evaluate the efficacy and adverse events of sotrovimab in preventing progression of mild to moderate COVID-19 to severe disease. Design, Setting, and Participants: Randomized clinical trial including 1057 nonhospitalized patients with symptomatic, mild to moderate COVID-19 and at least 1 risk factor for progression conducted at 57 sites in Brazil, Canada, Peru, Spain, and the US from August 27, 2020, through March 11, 2021; follow-up data were collected through April 8, 2021. Interventions: Patients were randomized (1:1) to an intravenous infusion with 500 mg of sotrovimab (n = 528) or placebo (n = 529). Main Outcomes and Measures: The primary outcome was the proportion of patients with COVID-19 progression through day 29 (all-cause hospitalization lasting >24 hours for acute illness management or death); 5 secondary outcomes were tested in hierarchal order, including a composite of all-cause emergency department (ED) visit, hospitalization of any duration for acute illness management, or death through day 29 and progression to severe or critical respiratory COVID-19 requiring supplemental oxygen or mechanical ventilation. Results: Enrollment was stopped early for efficacy at the prespecified interim analysis. Among 1057 patients randomized (median age, 53 years [IQR, 42-62], 20% were ≥65 years of age, and 65% Latinx), the median duration of follow-up was 103 days for sotrovimab and 102 days for placebo. All-cause hospitalization lasting longer than 24 hours or death was significantly reduced with sotrovimab (6/528 [1%]) vs placebo (30/529 [6%]) (adjusted relative risk [RR], 0.21 [95% CI, 0.09 to 0.50]; absolute difference, -4.53% [95% CI, -6.70% to -2.37%]; P < .001). Four of the 5 secondary outcomes were statistically significant in favor of sotrovimab, including reduced ED visit, hospitalization, or death (13/528 [2%] for sotrovimab vs 39/529 [7%] for placebo; adjusted RR, 0.34 [95% CI, 0.19 to 0.63]; absolute difference, -4.91% [95% CI, -7.50% to -2.32%]; P < .001) and progression to severe or critical respiratory COVID-19 (7/528 [1%] for sotrovimab vs 28/529 [5%] for placebo; adjusted RR, 0.26 [95% CI, 0.12 to 0.59]; absolute difference, -3.97% [95% CI, -6.11% to -1.82%]; P = .002). Adverse events were infrequent and similar between treatment groups (22% for sotrovimab vs 23% for placebo); the most common events were diarrhea with sotrovimab (n = 8; 2%) and COVID-19 pneumonia with placebo (n = 22; 4%). Conclusions and Relevance: Among nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression, a single intravenous dose of sotrovimab, compared with placebo, significantly reduced the risk of a composite end point of all-cause hospitalization or death through day 29. The findings support sotrovimab as a treatment option for nonhospitalized, high-risk patients with mild to moderate COVID-19, although efficacy against SARS-CoV-2 variants that have emerged since the study was completed is unknown. Trial Registration: ClinicalTrials.gov Identifier: NCT04545060.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2022.2832

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Metadata

Authors
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Rodrigues Falci, D., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Parra, S., Sager, J. E., Austin, D., Peppercorn, A., Alexander, E., Yeh, W. W., Brinson, C., Aldinger, M., Shapiro, A. E., COMET-ICE Investigators, Free, A., Johnson, K., Cordasco, E., Little, R., Bajwa, A., Doshi, A., Focil, A., Hussain, R. (., Bostick, G., Somodevilla, G., Ali, H., Kowalczyk, J., Mittal, S., Caso, J., Goisse, M., Espinal, L., Zepeda, L., Nguyen, T., Martinez, L., Alvarez, G., Pucillo, R., Seep, M., Parikh, N., Escobar, V., Curra, A., Dal Maso, V., O'Mahony, J., Ramacciotti, E., Diaz, J., Luz, K., Ruane, P., Mochlera, B., Roldan Sanchez, J., Hernandez, L., Fernandez, A., Leavitt, G., Azizad, M., Afzal, H., Fatakia, A., Narejos Perez, S., Stadnik, C. M., Gorgos, L., Sachdeva, Y., Segura, P., Quandros, C., Perry, R., & Sher, L.
Venue
JAMA
Published
2022-04-05
Volume
327
Issue
13
Pages
1236
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4220848096
Cited by
279
References
26
FWCI
30.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.